Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent discussions she has had with (a) the Chief Executive of NHS England and (b) NICE on regulatory approval of (i) Lecanemab, (ii) Donanemab and (iii) other medicines that could be used to manage the progression of Alzheimer’s disease.

The Department is working closely together with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence, NHS England, the devolved administrations, and the Dementia Mission to plan for the implementation of new dementia medicines, should they gain approval in the United Kingdom.

NHS England also has a programme of work overseeing national preparedness work ahead of regulatory decisions being made about the introduction of potential new disease modifying treatments for early Alzheimer’s disease. This includes partnering with other national agencies, proactively engaging with other key partners including patient groups, identifying opportunities for information sharing and collaboration, and supporting integrated care boards as they plan for local implementation.